Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael M Hoffmann

Showing results (21-30 of 98) with videos related to

Pageof 10
Sort By:
European Heart Journal|May 24, 2008
C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC studyTanja B Grammer, Winfried März, Wilfried Renner, et al.
Atherosclerosis|July 25, 2009
Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitusKarl Winkler, Michael M Hoffmann, Vera Krane, et al.
Blood Cells, Molecules & Diseases|November 18, 2011
High levels of brain-type creatine kinase activity in human platelets and leukocytes: a genetic anomaly with autosomal dominant inheritanceHeidwolf Arnold, Thomas F Wienker, Michael M Hoffmann, et al.
Current Drug Delivery|May 22, 2018
Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and DosingRomeo Ngoune, Christine Contini, Michael M Hoffmann, et al.
British Journal of Clinical Pharmacology|September 18, 2004
Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokineticsMargit Fröhlich, Michael M Hoffmann, Jürgen Burhenne, et al.
Journal of the American Society of Nephrology : JASN|February 22, 2001
Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathyMichael M Hoffmann, Hubert Scharnagl, Eleftheria Panagiotou, et al.
BMC Cardiovascular Disorders|August 29, 2013
Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical careDietrich Rothenbacher, Michael M Hoffmann, Lutz P Breitling, et al.
The American Journal of Cardiology|November 27, 2002
C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen Risk and Cardiovascular Health (LURIC) studyMarkus Nauck, Bernhard R Winkelmann, Michael M Hoffmann, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 20, 2002
The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarctionMarkus Nauck, Bernhard R Winkelmann, Michael M Hoffmann, et al.
Atherosclerosis|August 16, 2006
G-protein beta3 subunit (GNB3) gene polymorphisms and cardiovascular disease: the Ludwigshafen Risk and Cardiovascular Health (LURIC) studyWilfried Renner, Michael M Hoffmann, Gerda Grünbacher, et al.
Pageof 10

Showing results (21-30 of 98) with videos related to

Sort By:
Pageof 10
European Heart Journal|May 24, 2008
C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC studyTanja B Grammer, Winfried März, Wilfried Renner, et al.
Atherosclerosis|July 25, 2009
Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitusKarl Winkler, Michael M Hoffmann, Vera Krane, et al.
Blood Cells, Molecules & Diseases|November 18, 2011
High levels of brain-type creatine kinase activity in human platelets and leukocytes: a genetic anomaly with autosomal dominant inheritanceHeidwolf Arnold, Thomas F Wienker, Michael M Hoffmann, et al.
Current Drug Delivery|May 22, 2018
Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and DosingRomeo Ngoune, Christine Contini, Michael M Hoffmann, et al.
British Journal of Clinical Pharmacology|September 18, 2004
Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokineticsMargit Fröhlich, Michael M Hoffmann, Jürgen Burhenne, et al.
Journal of the American Society of Nephrology : JASN|February 22, 2001
Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathyMichael M Hoffmann, Hubert Scharnagl, Eleftheria Panagiotou, et al.
BMC Cardiovascular Disorders|August 29, 2013
Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical careDietrich Rothenbacher, Michael M Hoffmann, Lutz P Breitling, et al.
The American Journal of Cardiology|November 27, 2002
C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen Risk and Cardiovascular Health (LURIC) studyMarkus Nauck, Bernhard R Winkelmann, Michael M Hoffmann, et al.
Journal of Molecular Medicine (Berlin, Germany)|August 20, 2002
The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarctionMarkus Nauck, Bernhard R Winkelmann, Michael M Hoffmann, et al.
Atherosclerosis|August 16, 2006
G-protein beta3 subunit (GNB3) gene polymorphisms and cardiovascular disease: the Ludwigshafen Risk and Cardiovascular Health (LURIC) studyWilfried Renner, Michael M Hoffmann, Gerda Grünbacher, et al.
Pageof 10